{"id":"https://openalex.org/W2741767006","doi":"https://doi.org/10.1158/1538-7445.am2017-3160","title":"Abstract 3160: Sustained MAPK activation as a mechanism of resistance to osimertinib plus selumetinib in models of EGFR-mutant cancer","display_name":"Abstract 3160: Sustained MAPK activation as a mechanism of resistance to osimertinib plus selumetinib in models of EGFR-mutant cancer","publication_year":2017,"publication_date":"2017-07-01","ids":{"openalex":"https://openalex.org/W2741767006","doi":"https://doi.org/10.1158/1538-7445.am2017-3160","mag":"2741767006"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2017-3160","doi":"https://doi.org/10.1158/1538-7445.am2017-3160","is_oa":false,"landing_page_url":"http://doi.org/10.1158/1538-7445.am2017-3160","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5064049869","display_name":"David Westover","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Westover","raw_affiliation_strings":["1Vanderbilt-Ingram Cancer Center, Nashville, TN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Vanderbilt-Ingram Cancer Center, Nashville, TN;","institution_ids":["https://openalex.org/I4390039299"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025951912","display_name":"Catherine Belle Meador","orcid":"https://orcid.org/0000-0001-5006-3569","observed_orcids":["https://orcid.org/0000-0001-5006-3569"]},"institutions":[{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Catherine B. Meador","raw_affiliation_strings":["1Vanderbilt-Ingram Cancer Center, Nashville, TN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Vanderbilt-Ingram Cancer Center, Nashville, TN;","institution_ids":["https://openalex.org/I4390039299"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050389295","display_name":"Eiki Ichihara","orcid":"https://orcid.org/0000-0002-2966-106X","observed_orcids":["https://orcid.org/0000-0002-2966-106X"]},"institutions":[{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eiki Ichihara","raw_affiliation_strings":["1Vanderbilt-Ingram Cancer Center, Nashville, TN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Vanderbilt-Ingram Cancer Center, Nashville, TN;","institution_ids":["https://openalex.org/I4390039299"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026182914","display_name":"Hayden F. Byrd","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hayden F. Byrd","raw_affiliation_strings":["1Vanderbilt-Ingram Cancer Center, Nashville, TN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Vanderbilt-Ingram Cancer Center, Nashville, TN;","institution_ids":["https://openalex.org/I4390039299"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032576859","display_name":"Cath Eberlein","orcid":"https://orcid.org/0000-0002-7357-7789","observed_orcids":["https://orcid.org/0000-0002-7357-7789"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Cath Eberlein","raw_affiliation_strings":["2AstraZeneca Oncology, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2AstraZeneca Oncology, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089131845","display_name":"Yingjun Yan","orcid":"https://orcid.org/0000-0001-6963-7112","observed_orcids":["https://orcid.org/0000-0001-6963-7112"]},"institutions":[{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yingjun Yan","raw_affiliation_strings":["1Vanderbilt-Ingram Cancer Center, Nashville, TN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Vanderbilt-Ingram Cancer Center, Nashville, TN;","institution_ids":["https://openalex.org/I4390039299"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026352956","display_name":"Darren A.E. Cross","orcid":"https://orcid.org/0000-0002-5227-2871","observed_orcids":["https://orcid.org/0000-0002-5227-2871"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Darren A. Cross","raw_affiliation_strings":["2AstraZeneca Oncology, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2AstraZeneca Oncology, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5074068244","display_name":"Christine Marie Lovly","orcid":"https://orcid.org/0000-0002-3641-6361","observed_orcids":["https://orcid.org/0000-0002-3641-6361"]},"institutions":[{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christine M. Lovly","raw_affiliation_strings":["1Vanderbilt-Ingram Cancer Center, Nashville, TN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Vanderbilt-Ingram Cancer Center, Nashville, TN;","institution_ids":["https://openalex.org/I4390039299"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"77","issue":"13_Supplement","first_page":"3160","last_page":"3160"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/osimertinib","display_name":"osimertinib","score":0.9679999947547913},{"id":"https://openalex.org/keywords/selumetinib","display_name":"selumetinib","score":1.0},{"id":"https://openalex.org/keywords/egfr-mutant-lung-cancer","display_name":"EGFR-mutant lung cancer","score":0.8259999752044678},{"id":"https://openalex.org/keywords/acquired-drug-resistance","display_name":"acquired drug resistance","score":0.8130000233650208},{"id":"https://openalex.org/keywords/mapk-pathway-reactivation","display_name":"MAPK pathway reactivation","score":0.921999990940094},{"id":"https://openalex.org/keywords/ras-activation","display_name":"Ras activation","score":0.6660000085830688},{"id":"https://openalex.org/keywords/erk-inhibition","display_name":"ERK inhibition","score":0.6980000138282776},{"id":"https://openalex.org/keywords/pan-raf-inhibitor","display_name":"pan-RAF inhibitor","score":0.7440000176429749},{"id":"https://openalex.org/keywords/combination-therapy-resistance","display_name":"combination therapy resistance","score":0.7379999756813049},{"id":"https://openalex.org/keywords/egfr-t790m-mutation","display_name":"T790M mutation","score":0.7260000109672546},{"id":"https://openalex.org/keywords/mek-inhibitors","display_name":"MEK inhibitors","score":0.6710000038146973},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitor-resistance","display_name":"tyrosine kinase inhibitor resistance","score":0.6399999856948853},{"id":"https://openalex.org/keywords/isogenic-cell-lines","display_name":"isogenic cell lines","score":0.6549999713897705},{"id":"https://openalex.org/keywords/gene-expression-profiling","display_name":"gene expression profiling","score":0.6029999852180481}],"concepts":[{"id":"https://openalex.org/C2776087337","wikidata":"https://www.wikidata.org/wiki/Q7448840","display_name":"Selumetinib","level":5,"score":0.9727350473403931},{"id":"https://openalex.org/C2777626846","wikidata":"https://www.wikidata.org/wiki/Q21506464","display_name":"Osimertinib","level":5,"score":0.9652885794639587},{"id":"https://openalex.org/C2777930144","wikidata":"https://www.wikidata.org/wiki/Q25100112","display_name":"T790M","level":5,"score":0.6160778999328613},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.5664947032928467},{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.5440731048583984},{"id":"https://openalex.org/C2781249067","wikidata":"https://www.wikidata.org/wiki/Q17142288","display_name":"MEK inhibitor","level":4,"score":0.5430916547775269},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4767211973667145},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4476534128189087},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4373341500759125},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.34390121698379517},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.33688071370124817},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.29781806468963623},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.29684412479400635},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.20504552125930786},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.0957348644733429},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.08965548872947693}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2017-3160","doi":"https://doi.org/10.1158/1538-7445.am2017-3160","is_oa":false,"landing_page_url":"http://doi.org/10.1158/1538-7445.am2017-3160","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9513999819755554,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.4300000071525574,"id":"https://metadata.un.org/sdg/2","display_name":"Zero hunger"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2995877501","https://openalex.org/W3033316579","https://openalex.org/W2809980410","https://openalex.org/W4383873626","https://openalex.org/W3183041359","https://openalex.org/W2605449696","https://openalex.org/W7146734436","https://openalex.org/W7208642590","https://openalex.org/W2976334328","https://openalex.org/W4247064555"],"abstract_inverted_index":{"Abstract":[0],"INTRODUCTION:":[1],"Osimertinib":[2],"is":[3,68,229,310,353,370,383],"a":[4,50,153,289,343,349,371,415],"third-generation,":[5],"mutant-selective":[6,27],"epidermal":[7],"growth":[8,240,294],"factor":[9],"receptor":[10],"(EGFR)":[11],"tyrosine":[12],"kinase":[13],"inhibitor":[14,64,283,291],"(TKI)":[15],"recently":[16],"approved":[17],"for":[18,53,312,435],"the":[19,62,75,150,243,254,281,286,293,358,367,432],"treatment":[20,155,180],"of":[21,29,38,74,152,188,214,223,245,253,260,288,297,308,346,366,373,417,425,431],"T790M-positive":[22],"EGFR-mutant":[23,426],"lung":[24],"cancer.":[25],"The":[26],"nature":[28],"osimertinib":[30,60,95,118,133,159,246,298,328,336,376,420],"improves":[31],"its":[32,36],"tolerability":[33],"by":[34,83,242],"limiting":[35],"inhibition":[37,241,307],"wild-type":[39],"EGFR":[40,46],"compared":[41],"to":[42,94,104,117,132,138,195,207,239,263,280,335,348,375,419],"first-":[43],"and":[44,119,125,175,225,275,379],"second-generation":[45],"inhibitors,":[47],"making":[48],"it":[49],"good":[51],"candidate":[52],"rationally-designed":[54],"combination":[55,106,121,244,326,350],"therapies.":[56],"One":[57],"such":[58],"combination,":[59],"plus":[61,134,160,247,299,337,377,421],"MEK":[63,320],"selumetinib":[65,88,120,135,300,378,422],"(AZD6244;":[66],"ARRY-142886),":[67],"currently":[69,230,354],"being":[70,355],"studied":[71],"as":[72,139,414],"part":[73],"phase":[76],"1b":[77],"TATTON":[78],"trial":[79],"(NCT02143466).":[80],"Previous":[81],"work":[82],"our":[84],"group":[85],"demonstrated":[86],"that":[87,102,236,305,332,352,364,380],"may":[89],"delay":[90],"or":[91],"reverse":[92],"resistance":[93,103,116,313,347,374,418],"in":[96,110,123,126,173,216,271,301,314,325,329,357,386,423],"some":[97],"cases;":[98],"however,":[99],"we":[100,113,249],"anticipate":[101],"this":[105,381],"will":[107],"ultimately":[108],"develop":[109],"patients.":[111],"Here,":[112],"investigate":[114],"acquired":[115],"therapy":[122,351],"vitro":[124],"vivo.":[127],"DESIGN:":[128],"In":[129,183,233],"cells":[130,277],"sensitive":[131,238,279],"(hereafter":[136],"referred":[137],"combination-sensitive":[140,174,224],"cells),":[141],"ERK":[142,282],"phosphorylation":[143],"was":[144,171,205,269,323],"monitored":[145],"via":[146],"Western":[147,202],"blot":[148,203],"over":[149],"course":[151],"7-day":[154],"with":[156,181,327],"200":[157],"nM":[158],"1":[161],"\u00b5M":[162],"selumetinib.":[163,338],"To":[164],"detect":[165],"RAS-GTP,":[166],"an":[167,212,318],"active":[168],"RAS":[169,267],"precipitation":[170],"performed":[172],"combination-resistant":[176,184,226,272,302,387],"cell":[177,227,234,273,330],"lines":[178,228,235,331],"following":[179],"osimertinib.":[182],"cells,":[185,303],"pharmacologic":[186],"inhibitors":[187],"various":[189],"MAPK":[190,255,309,368,412],"pathway":[191,256,369,382],"components":[192],"were":[193,333],"used":[194,206],"assess":[196],"whether":[197],"they":[198],"could":[199],"restore":[200],"potency.":[201],"analysis":[204,213],"confirm":[208],"on-target":[209],"effects.":[210],"Lastly,":[211],"differences":[215],"gene":[217],"expression":[218],"between":[219],"four":[220],"isogenic":[221],"sets":[222],"ongoing.":[231],"RESULTS:":[232],"are":[237],"selumetinib,":[248],"observed":[250],"complete":[251],"re-activation":[252,365],"after":[257],"5":[258],"days":[259],"continuous":[261],"exposure":[262],"both":[264],"inhibitors.":[265],"Additionally,":[266],"activity":[268],"elevated":[270],"lines,":[274],"these":[276,315,361],"remained":[278],"SCH772984.":[284],"Likewise,":[285],"addition":[287],"pan-RAF":[290],"restored":[292],"inhibitory":[295],"effects":[296],"suggesting":[304],"incomplete":[306],"responsible":[311],"cells.":[316,388],"Furthermore,":[317],"alternative":[319],"inhibitor,":[321],"trametinib,":[322],"efficacious":[324],"resistant":[334],"CONCLUSION:":[339],"These":[340],"data":[341,362],"identify":[342],"potential":[344],"mechanism":[345,372,416],"tested":[356],"clinic.":[359],"Specifically,":[360],"demonstrate":[363],"still":[384],"targetable":[385],"Citation":[389],"Format:":[390],"David":[391],"Westover,":[392],"Catherine":[393],"B.":[394],"Meador,":[395],"Eiki":[396],"Ichihara,":[397],"Hayden":[398],"F.":[399],"Byrd,":[400],"Cath":[401],"Eberlein,":[402],"Yingjun":[403],"Yan,":[404],"Darren":[405],"A.":[406],"Cross,":[407],"Christine":[408],"M.":[409],"Lovly.":[410],"Sustained":[411],"activation":[413],"models":[424],"cancer":[427],"[abstract].":[428],"In:":[429],"Proceedings":[430],"American":[433],"Association":[434],"Cancer":[436,449],"Research":[437],"Annual":[438],"Meeting":[439],"2017;":[440],"2017":[441],"Apr":[442],"1-5;":[443],"Washington,":[444],"DC.":[445],"Philadelphia":[446],"(PA):":[447],"AACR;":[448],"Res":[450],"2017;77(13":[451],"Suppl):Abstract":[452],"nr":[453],"3160.":[454],"doi:10.1158/1538-7445.AM2017-3160":[455]},"counts_by_year":[],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2017-08-08T00:00:00"}